Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of morbidity and mortality worldwide (Bousquet et al., 2007; Global Initiative for Chronic Obstructive Lung Disease, 2022).COPD is an often progressive and complex illness characterized by chronic airflow limitation, systemic manifestations, and a high burden of comorbidity (GOLD, 2022). The main treatment target in COPD is relief of symptoms, including fatigue, cough, and breathlessness (Barnett, 2005;Vogelmeier et al., 2020). The symptom that patients often experience as most troublesome and limiting is breathlessness (Bowden et al., 2011;Sandberg et al., 2019). COPD is likely to progress over several years and include sudden exacerbations, making the disease unpredictable due to experiences of both good and bad days. Respiratory symptoms may vary in severity over hours, days, and weeks, but are generally worse in the mornings (Miravitlles et al., 2017). Good days are experienced when the breathing is easier, followed by bad days with severe breathlessness. This leads to patients living with uncertainty until the time of death, suffering periods of unpredictable exacerbations with uncertain outcomes (Ek et al., 2015).Patients with advanced COPD may develop chronic severe hypoxemia, requiring long-term oxygen-therapy (LTOT) (Hardinge et al., 2015;Jacobs et al., 2020). Although LTOT improves survival in chronic severe hypoxemia, patients with LTOT still have a high mortality rate, with a median survival time after starting the treat-